Jump to content

CF33 is an Oncolytic Virotherapy

Nev Black

Recommended Posts

Imugene is a company listed on the Australian Stock Exchange. (This is not a recommendation to buy shares in this company)

CF33 is an Oncolytic Virotherapy which will be used in a Phase 1 Trial, in Australia, starting next year. CF33 will be trailed on a number of cancers.

Unfortunately, Prostate Cancer was not on the list.  



04/11/2019   Imugene Receives $4.13 million R&D Tax Incentive





21/10/2019   CF33 Oncolytic Virus Clinical Trial Program Update




(The announcements below are publicly available on the Australian Stock Exchange Announcements page)

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...